An innovative new heart catheter, the IntellaTip MiFi™ XP catheter, pinpoints areas for therapy delivery. The device was given FDA approval in the United States in August for the treatment of atrial flutter, an arrhythmia that affects nearly one million people in the United States.

The catheter is engineered to deliver highly localized electrical information in real time. Innovative electrodes around the catheter’s tip provide electrograms of the heart with a higher resolution than any other ablation catheter. These electrograms help clinicians assess lesion maturation and differentiate viable from non-viable tissue.

“The catheter helps physicians pinpoint the areas for therapy delivery, which helps make a more precise diagnosis and treatment of rhythm atrial flutter,” said cardiovascular physician Tom McElderry, MD, associate professor of medicine and section chief of Electrophysiology in the University of Alabama at Birmingham’s Division of Cardiovascular Disease. He is the first surgeon to use the catheter in a patient in the US. He also worked with Boston Scientific for five years on the sensor technology.

The catheter, which is removed at the conclusion of the procedure, has a steerable sheath that enables it to gain access to the heart, facilitating catheter use in a variety of procedures, including treatment of atrial flutter, atrial fibrillation and ventricular tachycardia. Enhanced features, which include a soft distal tip, advanced shaft construction and an intuitive ergonomic handle, help clinicians deliver catheters consistently and safely during electrophysiology procedures.